Radiotherapy for brain metastasis and long-term survival

Abstract Patients with brain metastases (BM) can benefit from radiotherapy (RT), although the long-term benefits of RT remain unclear. We searched a Korean national health insurance claims database and identified 135,740 patients with newly diagnosed BM during 2002–2017. Propensity score matching (P...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kawngwoo Park, Gi Hwan Bae, Woo Kyung Kim, Chan-Jong Yoo, Cheol Wan Park, Soo-Ki Kim, Jihye Cha, Jin Wook Kim, Jaehun Jung
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f608677aa46346339be0216305b6774e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f608677aa46346339be0216305b6774e
record_format	dspace
spelling	oai:doaj.org-article:f608677aa46346339be0216305b6774e2021-12-02T18:03:21ZRadiotherapy for brain metastasis and long-term survival10.1038/s41598-021-87357-x2045-2322https://doaj.org/article/f608677aa46346339be0216305b6774e2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87357-xhttps://doaj.org/toc/2045-2322Abstract Patients with brain metastases (BM) can benefit from radiotherapy (RT), although the long-term benefits of RT remain unclear. We searched a Korean national health insurance claims database and identified 135,740 patients with newly diagnosed BM during 2002–2017. Propensity score matching (PSM) was used to evaluate survival according to RT modality, which included whole-brain radiotherapy (WBRT) and/or stereotactic radiosurgery (SRS). The 84,986 eligible patients were followed for a median interval of 6.6 months, and 37,046 patients underwent RT (43.6%). After the PSM, patients who underwent RT had significantly better overall survival after 1 year (42.4% vs. 35.3%, P < 0.001), although there was no significant difference at 2.6 years, and patients who did not undergo RT had better survival after 5 years. Among patients with BM from lung cancer, RT was also associated with a survival difference after 1 year (57.3% vs. 32.8%, P < 0.001) and a median survival increase of 3.7 months. The 1-year overall survival rate was significantly better for SRS than for WBRT (46.4% vs. 38.8%, P < 0.001). Among Korean patients with BM, especially patients with primary lung cancer, RT improved the short-term survival rate, and SRS appears to be more useful than WBRT in this setting.Kawngwoo ParkGi Hwan BaeWoo Kyung KimChan-Jong YooCheol Wan ParkSoo-Ki KimJihye ChaJin Wook KimJaehun JungNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kawngwoo Park Gi Hwan Bae Woo Kyung Kim Chan-Jong Yoo Cheol Wan Park Soo-Ki Kim Jihye Cha Jin Wook Kim Jaehun Jung Radiotherapy for brain metastasis and long-term survival
description	Abstract Patients with brain metastases (BM) can benefit from radiotherapy (RT), although the long-term benefits of RT remain unclear. We searched a Korean national health insurance claims database and identified 135,740 patients with newly diagnosed BM during 2002–2017. Propensity score matching (PSM) was used to evaluate survival according to RT modality, which included whole-brain radiotherapy (WBRT) and/or stereotactic radiosurgery (SRS). The 84,986 eligible patients were followed for a median interval of 6.6 months, and 37,046 patients underwent RT (43.6%). After the PSM, patients who underwent RT had significantly better overall survival after 1 year (42.4% vs. 35.3%, P < 0.001), although there was no significant difference at 2.6 years, and patients who did not undergo RT had better survival after 5 years. Among patients with BM from lung cancer, RT was also associated with a survival difference after 1 year (57.3% vs. 32.8%, P < 0.001) and a median survival increase of 3.7 months. The 1-year overall survival rate was significantly better for SRS than for WBRT (46.4% vs. 38.8%, P < 0.001). Among Korean patients with BM, especially patients with primary lung cancer, RT improved the short-term survival rate, and SRS appears to be more useful than WBRT in this setting.
format	article
author	Kawngwoo Park Gi Hwan Bae Woo Kyung Kim Chan-Jong Yoo Cheol Wan Park Soo-Ki Kim Jihye Cha Jin Wook Kim Jaehun Jung
author_facet	Kawngwoo Park Gi Hwan Bae Woo Kyung Kim Chan-Jong Yoo Cheol Wan Park Soo-Ki Kim Jihye Cha Jin Wook Kim Jaehun Jung
author_sort	Kawngwoo Park
title	Radiotherapy for brain metastasis and long-term survival
title_short	Radiotherapy for brain metastasis and long-term survival
title_full	Radiotherapy for brain metastasis and long-term survival
title_fullStr	Radiotherapy for brain metastasis and long-term survival
title_full_unstemmed	Radiotherapy for brain metastasis and long-term survival
title_sort	radiotherapy for brain metastasis and long-term survival
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f608677aa46346339be0216305b6774e
work_keys_str_mv	AT kawngwoopark radiotherapyforbrainmetastasisandlongtermsurvival AT gihwanbae radiotherapyforbrainmetastasisandlongtermsurvival AT wookyungkim radiotherapyforbrainmetastasisandlongtermsurvival AT chanjongyoo radiotherapyforbrainmetastasisandlongtermsurvival AT cheolwanpark radiotherapyforbrainmetastasisandlongtermsurvival AT sookikim radiotherapyforbrainmetastasisandlongtermsurvival AT jihyecha radiotherapyforbrainmetastasisandlongtermsurvival AT jinwookkim radiotherapyforbrainmetastasisandlongtermsurvival AT jaehunjung radiotherapyforbrainmetastasisandlongtermsurvival
_version_	1718378785369227264

Radiotherapy for brain metastasis and long-term survival

Ejemplares similares